Antibiotic dosing: Do we dose to cure the individual or do we treat the greater societal needs?

Therapy

Volumn 2, Issue 4, 2005, Pages 511-516

  Blondeau, Joseph M ^a   Tillotson, Glenn S ^b  

^a ROYAL UNIVERSITY HOSPITAL   (Canada)

^b Oscient Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIVIRUS AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CHLORAMPHENICOL; ERYTHROMYCIN; GATIFLOXACIN; GEMIFLOXACIN; GREPAFLOXACIN; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SULFONAMIDE; TETRACYCLINE; TOBRAMYCIN; TROVAFLOXACIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; BACTERIAL MUTATION; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTERIUM MUTANT; CLINICAL TRIAL; COST CONTROL; COST EFFECTIVENESS ANALYSIS; CROSS RESISTANCE; DOSE CALCULATION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MARKETING; DRUG POTENCY; DRUG TISSUE LEVEL; DRUG USE; EDITORIAL; ENTEROCOCCUS; ERADICATION THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; LOW DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; PHARMACODYNAMICS; PNEUMONIA; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT INFECTION; SIDE EFFECT; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS RESISTANCE;

EID: 22544476813     PISSN: 14750708     EISSN: None     Source Type: Journal    
DOI: 10.1586/14750708.2.4.511     Document Type: Editorial

References (34)

1. Bush K. Antibacterial drug discovery in the 21st century. Clin. Microbiol. Infect. 10, 10-17 (2004).
2. Gould JC. The laboratory control of antibiotic therapy Br. Med. Bull. 16, 29-34 (1960).
3. Hansen G, Blondeau JM. Mutant prevention concentration as a strategy to minimize antimicrobial resistance: a timely concept but will its acceptance be too late? Therapy 2, 61-66 (2005).
4. Frisch AW, Tripp JT, Barrett Jr CD, Pidgeon BE. Specific polysaccaride content of pneumoni lungs. J. Exp. Med. 76, 505-510 (1942).
5. Dagan R, Klugman KP, Craig WA, Baquero F. Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy. J. Antimicrob. Chemother. 47, 129-140 (2001).
6. Dong Y, Zhao X, Kreiswirth BN, Drlica K. Mutant prevention concentration as a measure of antibiotic potency: studies with clinical isolates of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 44, 2581-2584 (2000).
7. Blondeau J, Zhao X, Hansen GT, Drlica K. Mutant prevention concentrations (MPC) for fluoroquinolones with clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 45, 433-438 (2001).
8. Blondeau JM, Hansen G, Metzler KL, Hedlin P. The role of PK/PD parameters to avoid selection and increase of resistance: mutant prevention concentration. J. Chemo. 16, 1-19 (2004).
9. Anderson KB, Tan JS, File TM Jr., et al. Emergence of levofloxacin-resistant pneumococci in immunocompromised adults after therapy for community-acquired pneumonia. Clin. Infect. Dis. 37, 376-381 (2003).
10. Chen D MA, de Azavedo JC, Low DE, The Canadian Bacterial Surveillance Network: Decreased susceptibility of Streptococcus pneumonaie to fluoroquinolones in Canada. N. Engl. J. Med. 341, 233-239 (1999).
11. Davidson R, Cavalcanti R, Brunton JL, Bast DJ et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N. Engl. J. Med. 346, 747-750 (2002).
12. Urban C, Rahman N, Zhao X et al. Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy. J. Infect. Dis. 184, 794-798 (2001).
13. Blondeau JM, Hansen G, Metzler KL, Borsos S, Chau J. Optimal killing of Streptococcus pneumoniae by gemifloxacin, levofloxacin and moxifloxacin. R. Soc. Med. Press 15-26 (2002).
14. Blondeau JM, Borsos S, Hesje C, Blondeau LD. The killing of multidrug-resistant Streptococcus pneumoniae (MDRSP) by gatifloxacin (GA), gemifloxacin (GM), levofloxacin (Lfx) and moxifloxacin (Mfx) over a range of bacterial inoculums using 2 different drug concentrations. In: World Conference on Magic Bullets - to Celebrate Paul Ehrlich's 150th Birthday, Nurnberg, Germany (2004).
15. Ho PL, Yung RWH, Tsang DN, Que TL, Ho M, Seto WH. Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong Kong multicenter study in 2000. J. Antimicrob. Chemother. 48, 659-665 (2001).
16. Doern GV. Antimicrobial use and the emergence of antimicrobial resistance with Streptococcus pneumoniae in the United States. Clin. Infect. Dis. 33, S187-S192. (2001).
17. Low DE. Quinolone resistance among pneumococci: therapeutic and diagnostic implications. Clin. Infect. Dis. 38, S357-362 (2004).
18. Baquero F. Trends in antibiotic resistance of respiratory pathogens: an analysis and commentary on a collaborative surveillance study. Antimicrob. Agents Chemother.38(Suppl. A), 117-132 (1996).
19. Johnson AP. Antibiotic resistance among clinically important Gram-positive bacteria in the UK. J. Hosp. Infect. 40, 17-26 (1998).
20. Low DE. Fluoroquinolone-resistant pneumococci: Maybe resistance isn't futile? (Editorial Commentary). Clin. Infect. Dis. 40, 236-238 (2005).
21. Guillemot D, Carbon C, Balkau B et al. Low dosage and long treatment duration of β-lactam: risk factors for carriage of penicillin-resistant Streptococcus pneumoniae. JAMA 279, 394-395 (1998).
22. Hoban D, Waites K, Felmingham D. Antimicrobial susceptibility of community-acquired respiratory tract pathogens in North America in 1999-2000: findings of the PROTEKT surveillance study. Diag. Microbiol. Infect. Dis. 45, 251-259 (2003).
23. Doern GV, Brown SD. Antimicrobial susceptibility among community-acquired respiratory tract pathogens in the USA: data from PROTEKT US 2000-01. J. Infect. 48, 56-65 (2004).
24. Forrest A, Nix DI, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob. Agents Chemother. 37, 1073-1081 (1993).
25. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26, 1-12 (1998).
26. Turnidge J. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Drugs 58, 29-36 (1999).
27. File Jr. TM, Schlemmer B, Garau J, Cupo M, Young C, 049 Clinical Study Group. Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin. J. Antimicrob. Chemother. 48, 67-74 (2001).
28. Ball P, Wilson R, Mandell LA, Brown J, Henkel T, 069 Clinical Study Group. Efficacy of gemifloxacin in acute exacerbations of chronic bronchitis: a randomized, double-blind comparison with trovafloxacin. J. Chemo. 13, 288-298 (2001).
29. Hansen G, Metzler KL, Drlica K, Blondeau JM. Mutant prevention concentration of gemifloxacin for clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 47, 440-441 (2003).
30. Hansen GT BJ. Mutant Prevention Concentration (MPC) for quinolones an non-quinolone antimicrobial agents against clinical isolates of Pseudomonas aeruginosa and the effect of antibiotic concentrations. In: 22nd International Congress of Chemotherapy Amsterdam, Netherlands (2001).
31. Zhao X, Drlica K. Restricting the selection of antibiotic-resistant mutant bacteria: measurement and potential use of the mutant selection window. J. Infect. Dis. 185, 561-565 (2002).
32. Lu T, Zhao X, Li X, Hansen G, Blondeau J, Drlica K. Effect of chloramphenicol, erythromycin, moxifloxacin, penicillin and tetracycline concentration on the recovery of resistant mutants of Mycobacterium smegmatis and Staphylococcus aureus. J. Antimicrob. Chemother. 52, 61-64 (2003).
33. Metzler K, Hansen G, Hedlin P, Harding E, Drlica K, Blondeau JM. Comparison of minimal inhibitory and mutant prevention drug concentrations of 4 fluoroquinolones against clinical isolates of methicillin-susceptible and-resistant Staphylococcus aureus. Int. J. Antimicrob. Agents 24, 161-167 (2004).
34. Blondeau JM, Borsos S. Application of the resistance prevention concentration - (RPC) and minimal inhibitory concentration (MIC) of clinical isolates of Streptococcus pneumoniae (SP) against macrolides. In: World Conference on Magic Bullets, Nurnberg, Germany (2004).